|
|
Exchange: |
American Stock Exchange |
Security
Type: |
Common |
Shares
Out: |
135,340,000 |
Market
Cap: |
636.77(M) |
Last
Volume: |
11,363,101 |
Avg
Vol: |
11,331,537 |
52
Week Range: |
$1.84 - $5.59 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Co.'s primary program, molgramostim nebulizer solution is an inhaled biologic, specifically an inhaled granulocyte-macrophage colony-stimulating factor and is being developed for the treatment of autoimmune pulmonary alveolar proteinosis. Molgramostim nebulizer solution is administered once daily by inhalation via a nebulizer, the eFlow® Nebulizer System. The eFlow® Nebulizer System is a reusable electronic inhalation system. Molgramostim was also being investigated in cystic fibrosis (CF) and non-CF patients for the treatment of nontuberculous mycobacterial lung infection, a lung disorder.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
3,439,830 |
4,023,225 |
Total Buy Value |
$0 |
$0 |
$10,277,564 |
$11,106,809 |
Total People Bought |
0 |
0 |
12 |
12 |
Total Buy Transactions |
0 |
0 |
14 |
42 |
Total Shares Sold |
0 |
187,843 |
187,843 |
187,843 |
Total Sell Value |
$0 |
$885,322 |
$885,322 |
$885,322 |
Total People Sold |
0 |
3 |
3 |
3 |
Total Sell Transactions |
0 |
3 |
3 |
3 |
End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Erickson Anne |
Chief Business Officer |
|
2024-04-21 |
4 |
D |
$4.81 |
$1,833 |
D/D |
(381) |
353,697 |
|
- |
|
Erickson Anne |
Chief Business Officer |
|
2024-03-21 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
354,078 |
|
-4% |
|
Elam Nevan C |
Director |
|
2023-12-28 |
4 |
S |
$4.71 |
$442,291 |
D/D |
(93,843) |
22,500 |
|
3% |
|
Elam Nevan C |
Director |
|
2023-12-28 |
4 |
OE |
$0.82 |
$69,722 |
D/D |
53,758 |
116,343 |
|
- |
|
Lowrance David L |
CHIEF FINANCIAL OFFICER |
|
2023-12-28 |
4 |
S |
$4.71 |
$47,131 |
D/D |
(10,000) |
342,355 |
|
3% |
|
Pauls Matthew |
CHIEF EXECUTIVE OFFICER |
|
2023-12-28 |
4 |
GD |
$0.00 |
$0 |
D/D |
19,000 |
1,283,674 |
|
- |
|
Pauls Matthew |
CHIEF EXECUTIVE OFFICER |
|
2023-12-28 |
4 |
S |
$4.71 |
$395,900 |
D/D |
(84,000) |
1,302,674 |
|
3% |
|
Lowrance David L |
CHIEF FINANCIAL OFFICER |
|
2023-12-15 |
4 |
GD |
$0.00 |
$0 |
D/D |
20,000 |
352,355 |
|
- |
|
Pratt Raymond Dennis |
Chief Medical Officer |
|
2023-12-14 |
4 |
A |
$0.00 |
$0 |
D/D |
150,000 |
310,000 |
|
- |
|
Sun Ricky |
|
|
2023-12-14 |
4 |
A |
$0.00 |
$0 |
D/D |
22,500 |
22,500 |
|
- |
|
Pauls Matthew |
CHIEF EXECUTIVE OFFICER |
|
2023-12-14 |
4 |
A |
$0.00 |
$0 |
D/D |
450,000 |
1,386,674 |
|
- |
|
Pauls Matthew |
CHIEF EXECUTIVE OFFICER |
|
2023-12-14 |
4 |
D |
$4.45 |
$488,076 |
D/D |
(109,680) |
936,674 |
|
- |
|
Van Es-Johansson An |
Director |
|
2023-12-14 |
4 |
A |
$0.00 |
$0 |
D/D |
22,500 |
22,500 |
|
- |
|
Mccracken Joseph S |
Director |
|
2023-12-14 |
4 |
A |
$0.00 |
$0 |
D/D |
22,500 |
190,837 |
|
- |
|
Elam Nevan C |
Director |
|
2023-12-14 |
4 |
A |
$0.00 |
$0 |
D/D |
22,500 |
62,585 |
|
- |
|
Hawkins Richard J |
Director |
|
2023-12-14 |
4 |
A |
$0.00 |
$0 |
D/D |
22,500 |
35,241 |
|
- |
|
Lutz Robert Matthew |
Chief Operating Officer |
|
2023-12-14 |
4 |
A |
$0.00 |
$0 |
D/D |
160,000 |
300,000 |
|
- |
|
Ramsay David A |
Director |
|
2023-12-14 |
4 |
A |
$0.00 |
$0 |
D/D |
22,500 |
2,223,642 |
|
- |
|
Lowrance David L |
CHIEF FINANCIAL OFFICER |
|
2023-12-14 |
4 |
A |
$0.00 |
$0 |
D/D |
160,000 |
372,355 |
|
- |
|
Lowrance David L |
CHIEF FINANCIAL OFFICER |
|
2023-12-14 |
4 |
D |
$4.45 |
$135,449 |
D/D |
(30,438) |
212,355 |
|
- |
|
Hawkins Richard J |
Director |
|
2023-12-11 |
4 |
OE |
$0.82 |
$8,890 |
D/D |
10,841 |
12,741 |
|
- |
|
Elam Nevan C |
Director |
|
2023-12-11 |
4 |
OE |
$0.82 |
$8,890 |
D/D |
10,841 |
40,085 |
|
- |
|
Florence Anthony A. Jr. |
10% Owner |
|
2023-07-17 |
4 |
B |
$3.00 |
$999,999 |
I/I |
333,333 |
24,471,264 |
1.5 |
19% |
|
Makhzoumi Mohamad |
10% Owner |
|
2023-07-17 |
4 |
B |
$3.00 |
$999,999 |
I/I |
333,333 |
24,471,264 |
1.5 |
19% |
|
Behbahani Ali |
10% Owner |
|
2023-07-17 |
4 |
B |
$3.00 |
$999,999 |
I/I |
333,333 |
24,471,264 |
1.5 |
19% |
|
179 Records found
|
|
Page 1 of 8 |
|
|